Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial

Journal:

The BMJ

Published:

2025-10-21

DOI:

10.1136/bmj-2025-084314

Affiliations:

6

Authors:

23

Go to article

Institutions	Authors	Share
Haihe Laboratory of Cell Ecosystem, China	9.500000	0.41
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), China	9.500000	0.41
The Second Affiliated Hospital, KMU, China	1.000000	0.04
Henan Cancer Hospital, ZZU, China	1.000000	0.04
Affiliated Hospital, North China University of Science and Technology, China	1.000000	0.04
Tianjin People's Hospital, China	1.000000	0.04

Interested in Immunology?